Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
KRYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$122.80 - $207.84
Previous CloseN/A
Volume44.50K
Average Volume (3M)372.03K
Market Cap
$4.31B
Enterprise Value$3.42B
Total Cash (Recent Filing)$681.99M
Total Debt (Recent Filing)$1.62M
Price to Earnings (P/E)30.6
Beta0.78
Next Earnings
Nov 10, 2025EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.29
Shares Outstanding28,942,982
10 Day Avg. Volume241,733
30 Day Avg. Volume372,028
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.73
Price to Sales (P/S)15.42
P/FCF Ratio37.58
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit10.24
Enterprise Value/Ebitda22.58
Forecast
1Y Price Target
$200.56Price Target Upside33.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsPromising data for inhaled KB707 demonstrated monotherapy activity and durable responses in heavily pre-treated patients, including a 36% objective response rate (ORR).
International ExpansionRecent approvals in the EU and Japan should permit greater opportunities for topline growth ex-US.
Revenue PerformanceRevenue for the second quarter was $96.0 million, beating both estimate of $90.9 million and consensus of $92.2 million, representing a quarter-over-quarter increase of 9%.
Bears Say
Reimbursement DelaysKrystal mentioned that they are behind on the goal of reaching 720 reimbursement approvals originally targeted for September/October, with that target now shifted to early next year.
Revenue ExpectationsNear-term expectations for growth dampened as management expects 3Q revenue to be below 2Q numbers based on patient pausing trends.
Unpredictability ConcernsManagement cited Vyjuvek’s 'inherent unpredictability' which raises concerns about consistent performance.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $122.80 and its highest was $207.84 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $4.31B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 10, 2025 which is in 66 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Aug 04, 2025. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.185 by $0.105.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.09.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,942,982 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.29 in its last earnings report, beating expectations of $1.185. Following the earnings report the stock price went down -14.04%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
Krystal Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$200.56 (33.93% Upside)
$200.56 (33.93% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 59.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.58%
12-Months-Change
Fundamentals
Return on Equity
15.61%
Trailing 12-Months
Asset Growth
24.05%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Krystal Biotech's earnings call highlights strong financial performance and strategic global expansion, with significant revenue growth and profitability. However, challenges such as anticipated revenue decline in Q3, ongoing sales force scaling, and potential market entry delays in Europe and Japan present concerns.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$200.56
▲(33.93% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Axsome Therapeutics
―
Verona Pharma
―
Ownership Overview
22.32% Insiders
32.25% Mutual Funds
0.08% Other Institutional Investors
20.95% Public Companies and Individual Investors